



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0293

Inventors: Salceda et al.

Serial No.: 09/995,494

Filing Date: November 27, 2001


Examiner: Not Yet Assigned

Group Art Unit: 1645

Title: Compositions and Methods Relating to
Prostate Specific Genes and Proteins

I, Kathleen A. Tyrrell, Registration No. 38,350,
certify that this correspondence is being deposited
with the U.S. Postal Service as First Class mail in
an envelope addressed to the U.S. Patent and
Trademark Office, P.O. Box 2327, Arlington, VA 22202.

On this date: March 31, 2003


Kathleen A. Tyrrell, Registration No. 38,350

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,




Kathleen A. Tyrrell
Registration No. 38,350

Date: March 31, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 01

Form PTO-1449 Modified

List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce

Docket No.
DEX-0293

Serial No.
09/995,494

Applicant
Salceda et al.

Filing Date
November 27, 2001

Group
1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Database EMBL January 2, 2001 "Homo sapiens BAC clone RP11-335L23", Database accession no. AC019193 XP002230136
	AB	Bussemakers et al., "DD3:A New Prostate-specific Gene, Highly Overexpressed in Prostate Cancer ¹ ", 1999 Cancer Research 59:5975-5979 XP002923011
	AC	Bussemakers M.J.G., "Changes in Gene Expression and Targets for Therapy", Eur. Urol. 1999 35:408-412 XP000891885
	AD	Hubert et al., "STEAP:A prostate-specific cell-surface antigen highly expressed in human prostate tumors", Proc. Natl. Acad. Sci. 1999 96(25):14523-14528 XP-
	AE	Srikantan et al., "PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer", Proc. Natl. Acad. Sci. 2000 97(22):12216-12221
EXAMINER		DATE CONSIDERED